| This week's sponsor is FierceBiotech Drug Development Forum. | |  | FierceBiotech 2nd Drug Development Forum - September 25-27 in Boston
Sign up by Friday, August 11 to save $200 on Registration! Join 90+ executive-level speakers as they share advanced partnership and pipeline strategies. Learn to adapt to increased deal complexity, real world evidence, and digital technologies. |
Featured Story | | | Tuesday, August 8, 2017 Dermira will take on exclusive, worldwide rights to IL-13 monoclonal antibody lebrikizumab from Roche, although the Big Pharma holds on to its rights for the medication in certain indications. |
|
|
Top Stories Tuesday, August 8, 2017 Sellas Life Sciences has snagged itself a Nasdaq listing by merging with Galena Biopharma. The deal gives Sellas a route to public investors as it seeks to guide its Wilms tumor 1-targeting drug through phase 3 trials in acute myeloid leukemia and mesothelioma. Tuesday, August 8, 2017 FibroGen has convinced investors it has another potential blockbuster on its hands. Shares in the West Coast biotech shot up 60% after it posted top-line phase 2 pamrevlumab data that suggest the anti-connective tissue growth factor (CTGF) antibody can muscle in on a market fought over by Boehringer Ingelheim and Roche. Monday, August 7, 2017 Natural killer (NK) cells first earned their title as “killers” nearly 40 years ago when researchers observed the rapid immune response of these lymphocytes as they destroyed host cells infected with a virus or tumor cells. It seemed that NK cells could attach spontaneously without prior activation. Over time, researchers have learned more about the molecular mechanisms that regulate their activation and function. Tuesday, August 8, 2017 Last year, Juno was hit by a string of deaths in a test for its experimental CAR-T med; now its top-level executives are being investigated about whether they failed shareholders by not telling them more about the fatalities. Monday, August 7, 2017 Lysosomes break down old material in cells so the body can dispose of it. Now, scientists at Yale University are zeroing in on lysosomes in the brain, and they believe they’ve discovered how these “garbage disposal” units may contribute to the buildup of the amyloid plaques characteristic of Alzheimer’s disease. Monday, August 7, 2017 Neuros Medical raised $20 million to complete the pivotal study of its neuromodulation device for the management of postamputation pain. Tuesday, August 8, 2017 For a second time, the FDA has turned its back on Valeant Pharmaceuticals' NDA for a new eye drug because of manufacturing issues at a Bausch + Lomb plant. Tuesday, August 8, 2017 Over the past 10 years, we’ve covered scores of deals—and rumors of deals—be they small, large or mega. Some paid off. Some didn't. Which M&A moves were the decade's best and which were the worst? We're asking you to decide. Nominate your picks this week. Tuesday, August 8, 2017 Tuesday's dose of your biopharma news of note. Resources Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. |
|
